BBOT COO granted 758,222 stock options
BridgeBio Oncology Therapeutics COO and Principal Financial Officer Elmelech Idan received a grant of stock options for 758,222 shares of Common Stock.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
BridgeBio Oncology Therapeutics COO and Principal Financial Officer Elmelech Idan received a grant of stock options for 758,222 shares of Common Stock. The options have an exercise price of 7.6600 per share and expire on May 9, 2036. Vesting occurs in 48 substantially equal monthly installments beginning on April 20, 2026, contingent on continued service.
Insider Trade Summary
Grant/Award: 758,222 shares
Grant/Award
1 txn
Insider
Elmelech Idan
Role
COO & Principal Financial Ofcr
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 758,222 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy) — 758,222 contracts (Direct)
Footnotes (1)
- F1. 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of April 20, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date.
Key Figures
Stock options granted: 758,222 options
Exercise price: 7.6600 per share
Expiration date: May 9, 2036
+3 more
6 metrics
Stock options granted
758,222 options
Grant to COO & Principal Financial Officer
Exercise price
7.6600 per share
Strike price for granted stock options
Expiration date
May 9, 2036
Option term end for this grant
Underlying shares
758,222 shares
Common Stock underlying the options
Post-transaction derivative holdings
758,222 options
Total options held following transaction
Vesting schedule
1/48 monthly installments
Monthly vesting from April 20, 2026
Key Terms
Stock Option (Right to Buy), Grant, award, or other acquisition, exercise price, expiration date, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
exercise price financial
"conversion_or_exercise_price: "7.6600""
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: "2036-05-09T00:00:00.000Z""
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vesting financial
"footnote: "1/48th of the shares subject to such option vest and become exercisable...""
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did BBOT report for Elmelech Idan?
BridgeBio Oncology Therapeutics reported that COO and Principal Financial Officer Elmelech Idan received a grant of stock options for 758,222 shares of Common Stock. This is a compensation-related award, not an open-market trade, and increases his potential future equity exposure.
What are the key terms of Elmelech Idan’s BBOT stock option grant?
The grant covers 758,222 stock options with an exercise price of 7.6600 per share and an expiration date of May 9, 2036. Each option represents the right to buy one share of BridgeBio Oncology Therapeutics Common Stock under specified vesting conditions.
How do the BBOT stock options granted to Elmelech Idan vest?
One forty-eighth of the 758,222 options vests in substantially equal monthly installments on each monthly anniversary of April 20, 2026. Vesting on each date is conditioned on Elmelech Idan’s continuous service to BridgeBio Oncology Therapeutics, making it a long-term incentive structure.
Is the BBOT Form 4 transaction a purchase or a compensation award?
The Form 4 describes a compensation award, coded as a grant or other acquisition of derivative securities. The transaction is a stock option grant to Elmelech Idan, not an open-market purchase or sale, and reflects equity-based compensation rather than immediate cash investment or divestment.
How many BBOT options does Elmelech Idan hold after this grant?
After the reported transaction, Elmelech Idan holds 758,222 stock options directly according to the filing. This total reflects the newly granted options as derivative securities linked to BridgeBio Oncology Therapeutics Common Stock, subject to vesting and exercisability over the defined schedule.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates